MA39847A - Protéines de liaison à l'antigène se liant à wisp1 - Google Patents
Protéines de liaison à l'antigène se liant à wisp1Info
- Publication number
- MA39847A MA39847A MA039847A MA39847A MA39847A MA 39847 A MA39847 A MA 39847A MA 039847 A MA039847 A MA 039847A MA 39847 A MA39847 A MA 39847A MA 39847 A MA39847 A MA 39847A
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- wisp1
- derivatives
- polypeptides
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
Abstract
Cette invention concerne des compositions et des méthodes se rapportant ou dérivées d'anticorps anti-wisp1. Plus spécifiquement, cette invention concerne des anticorps entièrement humains qui se lient à wisp1, des fragments d'anticorps qui se lient à wisp1, des dérivés desdits anticorps, et des polypeptides contenant lesdits fragments qui se lient à wisp1. D'autres modes de réalisation encore concernent des acides nucléiques codant pour ces anticorps, fragments d'anticorps, dérivés et polypeptides, des cellules contenant lesdits polynucléotides, des procédés de préparation des anticorps, fragments d'anticorps, dérivés et polypeptides selon l'invention, et des méthodes pour les utiliser comprenant des méthodes destinées à traiter ou à diagnostiquer les sujets présentant des troubles ou des états pathologiques associés à wisp1. Une méthode destinée à traiter ou à prévenir divers cancers ou maladies inflammatoires et diverses maladies du cœur, des os/articulations ou du poumon est en outre décrite.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461979704P | 2014-04-15 | 2014-04-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA39847A true MA39847A (fr) | 2017-02-22 |
Family
ID=54324703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA039847A MA39847A (fr) | 2014-04-15 | 2015-04-14 | Protéines de liaison à l'antigène se liant à wisp1 |
Country Status (9)
Country | Link |
---|---|
US (2) | US10272154B2 (fr) |
EP (1) | EP3131574A4 (fr) |
JP (1) | JP2017513854A (fr) |
KR (1) | KR20160138580A (fr) |
CN (1) | CN106456732A (fr) |
AU (1) | AU2015247742A1 (fr) |
CA (1) | CA2945498A1 (fr) |
MA (1) | MA39847A (fr) |
WO (1) | WO2015160858A2 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015247742A1 (en) | 2014-04-15 | 2016-11-24 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind WISP1 |
EP3373968B1 (fr) | 2015-11-09 | 2024-04-17 | The Children's Hospital of Philadelphia | Glypicane 2 à utiliser en tant que marqueur cancéreux et cible thérapeutique |
CN108663524B (zh) * | 2018-05-18 | 2021-06-25 | 南昌大学第二附属医院 | 过表达FAT10扰乱WISP1蛋白和mRNA表达促进肝癌的进展 |
WO2020033398A1 (fr) * | 2018-08-06 | 2020-02-13 | The Trustees Of Columbia University In The City Of New York | Compositions et procédés pour le traitement de maladies pulmonaires dépendant de cellules atii |
EP3866852A4 (fr) * | 2018-10-19 | 2022-07-06 | The General Hospital Corporation | Compositions et méthodes de traitement de maladies hépatiques |
CN109535249B (zh) * | 2018-12-12 | 2021-06-01 | 广州市第八人民医院 | 一种单克隆抗体ZKns3G2及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL135704A (en) * | 1997-10-29 | 2008-04-13 | Genentech Inc | Method for the diagnosis of cancerous growth of cells by identifying the secreted polypeptide WISP-1 affected by WNT-1 |
US7455834B2 (en) * | 2002-06-29 | 2008-11-25 | Genentech, Inc. | Methods and compositions for modulating and detecting WISP activity |
JO3244B1 (ar) * | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
EA028647B1 (ru) * | 2012-01-31 | 2017-12-29 | Ридженерон Фармасьютикалз, Инк. | Антитела к asic1 и их применение |
AU2015247742A1 (en) | 2014-04-15 | 2016-11-24 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind WISP1 |
-
2015
- 2015-04-14 AU AU2015247742A patent/AU2015247742A1/en not_active Abandoned
- 2015-04-14 JP JP2016562892A patent/JP2017513854A/ja active Pending
- 2015-04-14 EP EP15779722.6A patent/EP3131574A4/fr not_active Withdrawn
- 2015-04-14 WO PCT/US2015/025829 patent/WO2015160858A2/fr active Application Filing
- 2015-04-14 CN CN201580027175.4A patent/CN106456732A/zh active Pending
- 2015-04-14 US US15/330,956 patent/US10272154B2/en active Active
- 2015-04-14 MA MA039847A patent/MA39847A/fr unknown
- 2015-04-14 CA CA2945498A patent/CA2945498A1/fr not_active Abandoned
- 2015-04-14 KR KR1020167031772A patent/KR20160138580A/ko unknown
-
2019
- 2019-04-03 US US16/374,731 patent/US11318202B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3131574A2 (fr) | 2017-02-22 |
WO2015160858A3 (fr) | 2015-12-17 |
US20190224316A1 (en) | 2019-07-25 |
CA2945498A1 (fr) | 2015-10-22 |
US11318202B2 (en) | 2022-05-03 |
US20170304442A1 (en) | 2017-10-26 |
US10272154B2 (en) | 2019-04-30 |
CN106456732A (zh) | 2017-02-22 |
EP3131574A4 (fr) | 2018-01-03 |
KR20160138580A (ko) | 2016-12-05 |
JP2017513854A (ja) | 2017-06-01 |
AU2015247742A1 (en) | 2016-11-24 |
WO2015160858A2 (fr) | 2015-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017500331A1 (en) | Antigen binding proteins that bind cxcr5 | |
WO2017015560A3 (fr) | Anticorps thérapeutiques qui se lient à lag3 | |
WO2014194302A3 (fr) | Protéines de liaison à l'antigène qui se lient à pd-1 | |
MX2017011406A (es) | Terapeuticos de anticuerpo que se unen a tim3. | |
MA39847A (fr) | Protéines de liaison à l'antigène se liant à wisp1 | |
WO2013181634A3 (fr) | Protéines liant un antigène qui lient pd-l1 | |
MX2021007947A (es) | Terapeuticos de anticuerpo que se unen a ctla4. | |
WO2013192596A3 (fr) | Protéines de liaison à un antigène qui se lient à ccr2 | |
ZA202005259B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
MX2017010793A (es) | Terapeuticos de anticuerpo que ligan cd137. | |
MX2017011329A (es) | Productos terapeuticos de anticuerpos que se enlazan a cd47. | |
WO2016164669A3 (fr) | Agents thérapeutiques de type anticorps se liant à cd38 | |
WO2013192594A3 (fr) | Protéines de liaison à un antigène qui se lient à c-met | |
MX2018009011A (es) | Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos. | |
JO3623B1 (ar) | البروتينات المرتبطة بمولد المستضاد st2 | |
PH12019500571A1 (en) | Anti-pd-1 antibodies | |
MY200162A (en) | Anti-gitr antibodies and uses thereof | |
PH12017500332A1 (en) | Antigen binding proteins that bind cxcr3 | |
WO2014066530A3 (fr) | Protéines de liaison à un antigène qui se lient à erbb3 | |
WO2014062245A3 (fr) | Protéines liant l'antigène qui lient dll-4 | |
WO2016164657A3 (fr) | Agents thérapeutiques de type anticorps se liant à cd123 | |
PH12017502020A1 (en) | Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor | |
TW201613971A (en) | Anti-epidermal growth factor receptor (EGFR) antibodies | |
WO2016063026A3 (fr) | Séquences de liaison sélectives pour la protéine nav | |
PH12019502449A1 (en) | Anti-jagged1 antigen binding proteins |